john coakley sr president kda sent following press release nih along comment great program begin think kennedy disease association partnering others future 'far fetched might think let look ahead five years open minds unlimited possibilities immediate release tuesday february est nih industry non profits join forces speed validation disease targets goal develop new treatments earlier beginning alzheimer type diabetes autoimmune disorders national institutes health biopharmaceutical companies several non profit organizations today launched unprecedented partnership transform current model identifying validating promising biological targets disease new diagnostics drug development accelerating medicines partnership amp aims distinguish biological targets disease likely respond new therapies characterize biological indicators disease known biomarkers foundation nih fnih amp partners invest million five years first projects focus alzheimer disease type diabetes autoimmune disorders rheumatoid arthritis systemic lupus erythematosus lupus critical groundbreaking element partnership agreement data analyses generated made publicly available broad biomedical community three five year milestone driven pilot projects disease areas could set stage broadening amp diseases conditions patients caregivers relying science find better faster ways detect treat disease improve quality life said nih director francis collins ph currently investing great deal money time avenues high failure rates patients families wait sectors biomedical enterprise agree new approaches sorely needed good news recent dramatic advances basic research opening new windows opportunity therapeutics continued dr collins challenge beyond scope one time work together new ways increase collective odds success believe partnership important first step represents sweeping effort date tackle vital issue result technological revolutions genomics imaging researchers able identify many changes genes proteins molecules predispose disease influence disease progression researchers identified thousands biological changes hold promise biomarkers drug targets small number pursued choosing wrong target result failures late development process costing time money ultimately lives currently developing drug early discovery food drug administration approval takes well decade failure rate percent consequence success costs billion amp rallies scientific key players innovation ecosystem unified way address one key challenges biopharma drug discovery development said mikael dolsten ph president worldwide research development pfizer type novel collaboration leverage strengths industry nih ensure expedite translation scientific knowledge next generation therapies address urgent needs alzheimer diabetes ra lupus patients amp two years making intense interactions etween scientists public private sectors progressive refinement goals strategy development support boston consulting group scientific project partnership management fnih effort amp partners developed research plans sharing costs expertise resources integrated governance structure enables best informed contributions science participants